IMRX Stock Summary and Trading Ideas (Immuneering - Class A | NASDAQ:IMRX)

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Immuneering - Class A trades on the NASDAQ stock market under the symbol IMRX.

As of June 2, 2026, IMRX stock price declined to $4.28 with 2,350,626 million shares trading.

IMRX has a beta of 1.25, meaning it tends to be more sensitive to market movements. IMRX has a correlation of 0.02 to the broad based SPY ETF.

IMRX has a market cap of $276.71 million. This is considered a Small Cap stock.

In the last 3 years, IMRX traded as high as $11.92 and as low as $1.00.

The top ETF exchange traded funds that IMRX belongs to (by Net Assets): VTI, VXF, IBB, IWC, AVSC.

IMRX has outperformed the market in the last year with a return of +150.3%, while the SPY ETF gained +30.1%. However, in the most recent history, IMRX shares have underperformed the stock market with its stock returning -14.2% in the last 3 month period and -12.1% for the last 2 week period, while SPY has returned +11.0% and +2.8%, respectively.

IMRX support price is $4.19 and resistance is $4.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMRX shares will trade within this expected range on the day.